Sign in

Research summary ·

Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review looked at drugs for idiopathic pulmonary fibrosis, or IPF. The team pooled phase 3 trials that tested each drug against placebo. The trials covered 5,386 people in all. No trial compared the drugs head to head. The team studied lung function decline, stopping treatment and death from any cause.

What they found

Pirfenidone and nintedanib each slowed lung function decline compared with placebo. Inhaled treprostinil also showed a good signal, mostly as an add-on drug. Nintedanib and inhaled treprostinil were linked to higher odds of stopping treatment. Both had an odds ratio of 1.39. Pirfenidone was the only drug linked to lower odds of death from any cause.

What it means for patients

The authors say lung function decline stays key but may not tell the drugs apart. They suggest weighing lung function, background drugs, stopping rates and death together. They call this a careful way to read phase 3 evidence.

Why it is not certain yet

No trial compared these drugs head to head. Without background therapy, results for several drugs were imprecise. The pirfenidone death finding used published pooled data and one Japanese trial. A review can only be as good as the studies in it.

Source

Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline.

PubMed · PMID 42907709

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Idiopathic pulmonary fibrosis publications